Join the 'Renal Cell Carcinoma' group to help and get support from people like you.

Renal Cell Carcinoma Blog

Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer

New Drug May Help Immune System Fight Cancer

Posted 16 May 2013 by Drugs.com

THURSDAY, May 16 – An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows. The drug binds to a protein called PD-L1 that sits on the surface of cancer cells and makes them invisible to the immune system, almost like a cloaking device. "That [the protein] allows the tumor cell to grow unchecked and cause harm to the patient," said study author Dr. Roy Herbst, chief of medical oncology at Yale University. But with the protein blocked, the immune system can see and destroy cancer cells. Of 140 patients in the pilot safety study, 29 (or 21 percent) initially saw significant tumor shrinkage after at least three months on the medication. Researchers say 26 patients have continued to respond over time, including some who have been on the drug for more than a year. One ... Read more

Related support groups: Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer

Cholesterol Drugs Might Boost Kidney Cancer Survival

Posted 7 May 2013 by Drugs.com

TUESDAY, May 7 – Cholesterol-lowering statin drugs that are taken by millions of Americans might also improve survival from a type of kidney cancer called renal cell carcinoma, a new study suggests. Statins – drugs such as Crestor, Lipitor, Pravachol and Zocor – have anti-inflammatory and cell self-destruction properties, and previous research has shown that these drugs may lower the risk of developing some types of cancer. The new research, presented Tuesday at the annual meeting of the American Urological Association in San Diego, suggests that the drugs might fight kidney cancer. "Given that one in four Americans over 45 years of age take a statin and renal cell carcinoma occurs most often in men ages 50 to 70, it may be prudent to prospectively evaluate if statins protect against [cancer] progression," study author Dr. Scott Eggener, an associate professor of urologic oncology at ... Read more

Related support groups: Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Renal Cell Carcinoma, Lovastatin, Rosuvastatin, Livalo, Red Yeast Rice, Pravachol, Lescol, Lescol XL, Mevacor, Baycol, Fluvastatin, Altoprev, Pitavastatin, Altocor

'Watch and Wait' Approach Often Best for Older Patients With Kidney Cancer

Posted 13 Feb 2013 by Drugs.com

TUESDAY, Feb. 12 – Sometimes, simply watching and waiting is a safe alternative to surgery for older patients with small kidney tumors, a new study suggests. "Physicians can comfortably tell an elderly patient, especially a patient that is not healthy enough to tolerate general anesthesia and surgery, that the likelihood of dying of kidney cancer is low and that kidney surgery is unlikely to extend their lives," study lead author Dr. William Huang, an assistant professor of urologic oncology at NYU Medical Center, said in a news release from the American Society of Clinical Oncology (ASCO). The findings are to be presented Saturday at an ASCO conference in New York City. Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal. In their study, Huang's team analyzed data from more than 8,300 patients aged 66 and older who were ... Read more

Related support groups: Renal Cell Carcinoma

Cancer Drug Doesn't Speed Up Tumor Growth, Researchers Say

Posted 7 Feb 2013 by Drugs.com

THURSDAY, Feb. 7 – The anticancer drug Sutent (sunitinib) does not cause tumors to grow faster after treatment ends, according to a new study. Previous research in animals suggested that tumor growth may accelerate after patients stopped taking Sutent. The new findings, from a study of kidney cancer patients, indicate that the drug does not pose lingering risks for humans. The researchers analyzed data from a phase 3 clinical trial that led to Sutent's approval. They concluded that regardless of how long patients took the drug, it did not cause harm, did not speed up tumor growth and survival was not shortened after treatment ended, according to the findings published online Feb. 7 in the journal Cell Reports. During treatment, Sutent slowed tumor growth and extended patients' lives, the investigators pointed out in a journal news release. Sutent, which is approved for the treatment of ... Read more

Related support groups: Renal Cell Carcinoma, Sutent, Sunitinib

Novel Drugs Show Early Promise Against Several Cancers

Posted 4 Jun 2012 by Drugs.com

SATURDAY, June 2 – Two related "immunotherapy" drugs show early evidence of being able to thwart a variety of tough-to-treat, advanced cancers. About one-quarter of patients with advanced melanoma, kidney or lung cancer saw their tumors shrink when taking one of the two drugs, researchers reported Saturday. But the findings are extremely preliminary. Phase 1 studies such as this aren't designed to look at tumor shrinkage at all, but simply to establish dosage. And the therapies produced some serious side effects. While seeing results in a study such as this is "exciting," said Dr. Len Lichtenfeld, deputy chief medical officer at the American Cancer Society, "this was not the focus of the study." The two experimental drugs are antibodies that target two proteins in a key pathway of the immune system. "Cancers seem to have co-opted this pathway to enable them to fly below the radar of ... Read more

Related support groups: Cancer, Renal Cell Carcinoma, Lung Cancer, Skin Cancer, Melanoma

Kidney Cancer Patients Fare Better With Tumor Removal Only

Posted 17 Apr 2012 by Drugs.com

TUESDAY, April 17 – Kidney cancer patients who have only the tumor removed, not the entire kidney, have higher survival rates, a new study finds. The research involved more than 7,000 Medicare patients with early-stage kidney cancer who underwent surgery to remove either the entire organ (radical nephrectomy) or only the tumor and a small margin of healthy tissue around it (partial nephrectomy). After an average follow-up of five years, 25 percent of patients who had a partial nephrectomy had died, compared with 42 percent of those who had a radical nephrectomy, researchers at the University of Michigan Comprehensive Cancer Center reported. The study appears in the April 18 issue of the Journal of the American Medical Association. "For patients who are candidates for partial nephrectomy, it should be the preferred treatment option. We found that patients who were younger or had ... Read more

Related support groups: Renal Cell Carcinoma

Immune-Based Drug Combo Might Extend Cancer Survival

Posted 2 Apr 2012 by Drugs.com

MONDAY, April 2 – Cancer patients who receive a combination of low-dose interleukin-2 and retinoic acid after conventional therapy seem to live longer than those who don't get the combination. These new study findings, slated for presentation this week at the annual meeting of the American Association for Cancer Research in Chicago, were seen across individuals with many different forms of advanced malignancies, including breast, lung and colon cancers. Retinoic acid is derived from vitamin A. Interleukin-2, a compound that fortifies the immune system, is approved at high doses to treat "metastatic" melanoma and kidney cancer. Metastatic means that a cancer has spread. The study showed that "these biological compounds may work at low doses. Bigger doses are not always better," said lead author Dr. Francesco Recchia, director of the oncology department at Civilian Hospital in Avezzano, ... Read more

Related support groups: Cancer, Breast Cancer, Renal Cell Carcinoma, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Melanoma - Metastatic, Small Cell Lung Cancer, Gastric Cancer

Inlyta Approved for Advanced Kidney Cancer

Posted 30 Jan 2012 by Drugs.com

FRIDAY, Jan. 27 – Inlyta (axitinib) has been approved by the U.S. Food and Drug Administration to treat advanced renal cell carcinoma in people who haven't responded to another drug. Renal cell carcinoma is a form of kidney cancer that begins in tissue that lines the kidney's small tubes. Inlyta blocks proteins that help fuel tumor growth in this area, the FDA said in a news release. Six medications had been sanctioned previously for advanced kidney cancer, the agency said. In a study of 723 people with the advanced form of kidney cancer, the most common side effects of Inlyta included diarrhea, high blood pressure, fatigue, loss of appetite, nausea, loss of voice, weight loss, weakness and constipation. Among some patients, Inlyta also caused significant bleeding, which in some cases proved fatal. The FDA also warned that people with high blood pressure should make sure the problem is ... Read more

Related support groups: Renal Cell Carcinoma

FDA Approves Inlyta for Advanced Renal Cell Carcinoma

Posted 27 Jan 2012 by Drugs.com

FRIDAY, January 27, 2012 – The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer. Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. Inlyta works by blocking certain proteins called kinases that play a role in tumor growth and cancer progression. Inlyta is a pill that patients take twice a day. “This is the seventh drug that has been approved for the treatment of metastatic or advanced kidney cell cancer since 2005,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Collectively, this unprecedented level of drug development within this time period has significantly altered the treatment parad ... Read more

Related support groups: Renal Cell Carcinoma

Cancer Patients Should Ask Doctors to Use Simple Terms

Posted 28 Sep 2011 by Drugs.com

WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more

Related support groups: Cancer, Provera, Methotrexate, Breast Cancer, Depo-Provera, Lupron, Accutane, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Lupron Depot, Femara, Gleevec, Fluorouracil, Claravis, Renal Cell Carcinoma, Lung Cancer, Zoladex, Tretinoin

NSAID Painkillers Linked to Risk of Kidney Cancer

Posted 12 Sep 2011 by Drugs.com

MONDAY, Sept. 12 – The long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as Advil, Motrin and Aleve may slightly increase the risk for developing kidney cancer, Harvard researchers report. Millions of people use these drugs regularly for pain and they have been associated with reducing the risk of some cancers, the researchers added. "NSAIDs have been associated with a reduced risk of several types of cancer, including colorectal, breast and prostate," said lead researcher Eunyoung Cho, an assistant professor of medicine at Brigham and Women's Hospital and Harvard Medical School. "Our study raises a contradicting possibility that non-aspirin NSAIDs may elevate the risk of certain types of cancer." "If our studies are confirmed, risks and benefits should be considered in deciding whether to use analgesics, especially for long duration," she added. The report was ... Read more

Related support groups: Ibuprofen, Naproxen, Meloxicam, Advil, Diclofenac, Voltaren, Mobic, Aleve, Motrin, Indomethacin, Toradol, Renal Cell Carcinoma, Etodolac, Nabumetone, Flector, Ketorolac, Arthrotec, Relafen, Naprosyn, Lodine

Agent Orange Linked to Kidney Cancer: Study

Posted 15 May 2011 by Drugs.com

SATURDAY, May 14 – There appears to be a link between Agent Orange and kidney cancer in U.S. veterans exposed to the herbicide in Vietnam, a new study suggests. Researchers at the Veterans Affairs Medical Center in Shreveport, La. examined the records of 297 patients diagnosed with kidney cancer between 1987 and 2009. Thirteen of the patients, aged 39 to 63 when they were diagnosed, said they had been exposed to Agent Orange. Documented exposure to the herbicide and pathology reports were available for 10 of the patients. The researchers reviewed these patients' age at diagnosis, tumor size, side of lesion, pathology and survival. Nine of the 10 patients had clear-cell cancers, which typically have worse outcomes than papillary tumors, which appeared in one patient. One patient had both clear-cell and papillary cancers. During the average follow-up of 54 months, four patients developed ... Read more

Related support groups: Renal Cell Carcinoma

Fewer Cancer Patients May Be Depressed Than Thought

Posted 20 Jan 2011 by Drugs.com

THURSDAY, Jan. 20 – The rate of depression among cancer patients may be lower than previously believed, a new study indicates. An international team of researchers analyzed 94 studies involving more than 14,000 patients and found that about one-sixth of cancer patients suffer depression and about one-third have a more widely defined mood disorder. Only modest rates of depression and anxiety occurred in cancer patients in the first five years after diagnosis, which suggests that depression is not inevitable in these patients, the researchers said. Only when it was combined with other mood disorders was depression common, occurring in 30 percent of hospitalized cancer patients. The study is published online Jan. 19 in The Lancet Oncology. Rates of depression and anxiety were not significantly different between patients receiving palliative care (care designed to ease pain and increase ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, Lung Cancer, Colorectal Cancer, Breast Cancer, Metastatic, Basal Cell Carcinoma, Non-Small Cell Lung Cancer, Brain Tumor, Pancreatic Cancer, Skin Cancer, Ovarian Cancer, Melanoma, Breast Cancer - Adjuvant, Osteosarcoma, Endometrial Cancer, Bladder Cancer, Cervical Cancer, Melanoma - Metastatic

1 in 5 Cancer Survivors Suffers Chronic Pain, Study Finds

Posted 20 Jan 2011 by Drugs.com

WEDNESDAY, Jan. 19 – More than 40 percent of cancer survivors experience pain, and the risk is highest among black and female patients, finds a new study. Researchers at the University of Michigan Health System surveyed nearly 200 U.S. cancer survivors and found that 43 percent had experienced pain since their diagnosis, and 20 percent suffered chronic cancer-related pain at least two years later. Among white patients, the most significant source of pain was cancer surgery (53.8 percent), and among black patients the greatest source of pain was cancer treatment (46.2 percent), according to the report. In addition, the study found that compared to men, women had more pain, more pain flare-ups, more disability due to pain and were more depressed because of pain. The authors also noted that black patients were more likely to report greater severity of pain and more pain-related ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, Lung Cancer, Colorectal Cancer, Breast Cancer, Metastatic, Basal Cell Carcinoma, Non-Small Cell Lung Cancer, Brain Tumor, Pancreatic Cancer, Ovarian Cancer, Skin Cancer, Melanoma, Breast Cancer - Adjuvant, Osteosarcoma, Endometrial Cancer, Bladder Cancer, Cervical Cancer, Melanoma - Metastatic

Demand for Radiation Therapy Predicted to Exceed Supply

Posted 21 Oct 2010 by Drugs.com

THURSDAY, Oct. 21 – Over the next decade, the growth in demand for radiation therapy in the United States will be 10 times greater than the increase in new radiation oncologists, a difference that could affect cancer patients' access to treatment, according to a new study. Between 2010 and 2020, the number of patients requiring radiation therapy will increase 22 percent but the number of full-time radiation oncologists entering the workforce will increase just 2 percent, said researchers at the University of Texas M.D. Anderson Cancer Center in Houston and colleagues. They based their predictions on projections that this year 3,943 radiation oncologists will treat an estimated 470,000 patients in the United States. The large increase in demand for radiation therapy will be partly due to growing numbers of older adults and minorities, groups in which certain types of cancers are more ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, Lung Cancer, Breast Cancer, Metastatic, Colorectal Cancer, Basal Cell Carcinoma, Non-Small Cell Lung Cancer, Brain Tumor, Pancreatic Cancer, Ovarian Cancer, Skin Cancer, Melanoma, Breast Cancer - Adjuvant, Osteosarcoma, Endometrial Cancer, Bladder Cancer, Cervical Cancer, Melanoma - Metastatic

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Wilms' Tumor, Cancer

Related Drug Support Groups

Provera, Depo-Provera, medroxyprogesterone, Votrient, Tarceva, Avastin, Xeloda, Sutent, Afinitor, view more... Nexavar, sunitinib, PegIntron, pazopanib, capecitabine, erlotinib, sorafenib, everolimus, peginterferon alfa-2b, Torisel, bevacizumab, Inlyta, interferon alfa-2a, Depo-Provera Contraceptive, Proleukin, axitinib, aldesleukin, depo-subQ provera 104, Roferon-A, Amen, temsirolimus, Cycrin, Curretab